Belite Bio (BLTE) Earnings Analysis

Belite Bio (BLTE) next reports earnings on 2026-08-10, consensus EPS -0.73 USD. Last quarter (2026-05-20) it beat with EPS -0.34 USD vs -0.6 USD est (+43.3%). It has beaten estimates in 2/6 recent quarters (33%). Trailing P/E -61.62.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BLTE next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-0.73 USD
Revenue estimaten/a

BLTE earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-20-0.34 USD-0.6 USD+43.3%Beat
2026-03-02-0.38 USD-0.56 USD+32.1%Beat
2025-11-10-0.65 USD-0.53 USD-22.6%Miss
2025-08-11-0.5 USD-0.47 USD-6.4%Miss
2025-03-17-0.32 USD-0.3 USD-6.7%Miss
2024-08-09-0.31 USD-0.28 USD-10.7%Miss

Beat rate: 2/6 (33%) over reported quarters with consensus data.

BLTE valuation and analyst view

Trailing P/E-61.62
Trailing EPS-2.26423 USD
Price / book7.87
Dividend yield0.00%
Market cap6.26B
Analyst consensusBuy (6 buy / 0 hold / 0 sell)
Avg price target216 USD

Related research pages

Frequently asked questions

When is Belite Bio (BLTE)'s next earnings date?

Belite Bio is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.73 USD.

Did BLTE beat earnings last quarter?

In its 2026-05-20 report, BLTE posted EPS of -0.34 USD versus a -0.6 USD estimate — a beat of 43.3%.

What is BLTE's earnings track record?

Over the last 6 reported quarters with consensus data, BLTE beat estimates 2 times (33%).

What is BLTE's current P/E ratio and EPS?

BLTE trades at a trailing P/E of -61.62 on trailing EPS of -2.264234273602232 USD.

What do analysts rate BLTE?

Analyst consensus is "Buy" across 6 ratings (0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 216 USD.